Companies › Atea Pharmaceuticals
4 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Infectious disease, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bemnifosbuvir-Ruzasvir (BEM/RZR) HCV NS5B polymerase inhibitor and NS5A inhibitor combination | NS5B, NS5A | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | Dec 2026 |
| AT-587 | – | Phase 1 | Hepatitis E | Dec 2026 |
| Bemnifosbuvir (BEM, AT-527) Nucleoside reverse transcriptase inhibitor | – | Phase 1 | Healthy Volunteer Study | – |
| Ruzasvir (AT-038) Nonstructural protein 5A inhibitor | – | Phase 1 | Healthy Volunteer Study | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06868264 | Bemnifosbuvir-Ruzasvir (BEM/RZR) | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | Infectious disease | Jun 2026 |
| NCT07314346 | Bemnifosbuvir (BEM, AT-527) | Phase 1 | Healthy Volunteer Study | Other | Jul 2026 |
| NCT07314346 | Ruzasvir (AT-038) | Phase 1 | Healthy Volunteer Study | Other | Jul 2026 |
| NCT07728487 | AT-587 | Phase 1 | Hepatitis E | Infectious disease | Dec 2026 |
| NCT07037277 | Bemnifosbuvir-Ruzasvir (BEM/RZR) | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | Infectious disease | Dec 2026 |
Cash and short-term investments of $191m on 2026-09-30; operating cash outflow about $151m a year; runway about 15 months at that burn, to Jan 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Shanghai Ark Biopharmaceutical Ensysce Biosciences Aligos Therapeutics BioAegis Therapeutics Basilea Pharmaceutica
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.